These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34863304)

  • 41. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of COVID convalescent plasma therapy in hospitalized moderate coronavirus disease 2019 patients.
    Irawan C; Rumende CM; Sukrisman L; Pitoyo CW; Suwarto S; Susilo A; Mulansari NA; Harahap AT; Priantono D; Syafitri R; Chunaeni S; Ritchie NK
    J Infect Dev Ctries; 2023 Jan; 17(1):43-51. PubMed ID: 36795929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
    Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.
    Kirenga B; Byakika-Kibwika P; Muttamba W; Kayongo A; Loryndah NO; Mugenyi L; Kiwanuka N; Lusiba J; Atukunda A; Mugume R; Ssali F; Ddungu H; Katagira W; Sekibira R; Kityo C; Kyeyune D; Acana S; Aanyu-Tukamuhebwa H; Kabweru W; Nakwagala F; Bagaya BS; Kimuli I; Nantanda R; Buregyeya E; Byarugaba B; Olaro C; Mwebesa H; Joloba ML; Siddharthan T; Bazeyo W
    BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34376401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A matched cohort study of convalescent plasma therapy for COVID-19.
    Sostin OV; Rajapakse P; Cruser B; Wakefield D; Cruser D; Petrini J
    J Clin Apher; 2021 Aug; 36(4):523-532. PubMed ID: 33616257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection.
    Baldeón ME; Maldonado A; Ochoa-Andrade M; Largo C; Pesantez M; Herdoiza M; Granja G; Bonifaz M; Espejo H; Mora F; Abril-López P; Armijo LKR; Pacheco V; Salazar R; Reinthaller S; Zertuche F; Fornasini M
    Transfus Med; 2022 Apr; 32(2):153-161. PubMed ID: 35001439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In patients hospitalized with COVID-19, adding convalescent plasma to usual care did not reduce 28-d mortality.
    Dionne JC; Oczkowski SJW
    Ann Intern Med; 2021 Oct; 174(10):JC113. PubMed ID: 34606320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
    Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B
    PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.
    Greenbaum U; Klein K; Martinez F; Song J; Thall PF; Ramdial JL; Knape C; Aung FM; Scroggins J; Knopfelmacher A; Mulanovich V; Borjan J; Adachi J; Muthu M; Leung C; Medina MC; Champlin R; Olson A; Alousi A; Rezvani K; Shpall EJ
    Front Immunol; 2021; 12():675679. PubMed ID: 33995420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.
    Ray Y; Paul SR; Bandopadhyay P; D'Rozario R; Sarif J; Raychaudhuri D; Bhowmik D; Lahiri A; Vasudevan JS; Maurya R; Kanakan A; Sharma S; Kumar M; Singh P; Roy R; Chaudhury K; Maiti R; Bagchi S; Maiti A; Perwez MM; Mondal A; Tewari A; Mandal S; Roy A; Saha M; Biswas D; Maiti C; Bhaduri R; Chakraborty S; Sarkar BS; Haldar A; Saha B; Sengupta S; Pandey R; Chatterjee S; Bhattacharya P; Paul S; Ganguly D
    Nat Commun; 2022 Jan; 13(1):383. PubMed ID: 35046397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden.
    Dillner J; Ursing J
    BMJ Open; 2021 Dec; 11(12):e048337. PubMed ID: 34880010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
    Avendaño-Solá C; Ramos-Martínez A; Muñez-Rubio E; Ruiz-Antorán B; Malo de Molina R; Torres F; Fernández-Cruz A; Calderón-Parra J; Payares-Herrera C; Díaz de Santiago A; Romera-Martínez I; Pintos I; Lora-Tamayo J; Mancheño-Losa M; Paciello ML; Martínez-González AL; Vidán-Estévez J; Nuñez-Orantos MJ; Saez-Serrano MI; Porras-Leal ML; Jarilla-Fernández MC; Villares P; de Oteyza JP; Ramos-Garrido A; Blanco L; Madrigal-Sánchez ME; Rubio-Batllés M; Velasco-Iglesias A; Paño-Pardo JR; Moreno-Chulilla JA; Muñiz-Díaz E; Casas-Flecha I; Pérez-Olmeda M; García-Pérez J; Alcamí J; Bueno JL; Duarte RF;
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34473652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
    Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB
    JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Convalescent plasma for covid19 - How long should a donor be excluded from donation?
    Kutner JM; Bonet-Bub C; Yokoyama APH; Sakashita AM; Pinho JRR; Hamerschlak N; Rizzo LV
    Transfus Apher Sci; 2020 Oct; 59(5):102873. PubMed ID: 32713627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.